Inventor · disambiguated record
William R. Ewing
Also filed as: EWING WILLIAM · EWING WILLIAM R
85 granted patents·14 pending applications·647 citations·filing 1990–2023
99Inventor score
Files withBRISTOL MYERS SQUIBB CO70RHONE POULENC RORER PHARMA6EWING WILLIAM R4AVENTIS PHARMA GMBH3SUN CHONGQING3
Top patents by PatentIndex Score
99 records- 0196US9453018B2Pyrimidinones as factor XIa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 27, 2016·13 cites·17 claims
- 0293US10208068B2Macrocycles as factor XIa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Feb 19, 2019·5 cites·3 claims
- 0393US7858639B2Bicyclic heterocycles as cannabinoid-1 receptor modulatorsBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Dec 28, 2010·30 cites·15 claims
- 0492US9902742B2Macrocycles as factor XIa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Feb 27, 2018·5 cites·13 claims
- 0592US9611274B2Macrocycles as factor XIa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Apr 4, 2017·5 cites·14 claims
- 0692US8557841B2Heterocyclic aromatic compounds useful as growth hormone secretagoguesYU GUIXUE·Filed 2012·Granted Oct 15, 2013·17 cites·1 claims
- 0792US7517991B2N-sulfonylpiperidine cannabinoid receptor 1 antagonistsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Apr 14, 2009·11 cites·11 claims
- 0891US9221818B2Macrocycles as factor XIa inhibitorsPINTO DONALD J P·Filed 2012·Granted Dec 29, 2015·13 cites·11 claims
- 0991US7884113B2Tetrahydroquinoline derivatives as cannabinoid receptor modulatorsBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Feb 8, 2011·8 cites·8 claims
- 1091US7417028B2Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditionsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Aug 26, 2008·20 cites·22 claims
- 1190US8119808B2Tetrahydroquinoline derivatives as cannabinoid receptor modulatorsSUN CHONGQING·Filed 2011·Granted Feb 21, 2012·8 cites·9 claims
- 1290US7238670B2Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditionsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Jul 3, 2007·32 cites·27 claims
- 1390US5612353ASubstituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compoundsRHONE POULENC RORER PHARMA·Filed 1995·Granted Mar 18, 1997·59 cites·12 claims
- 1488US6281227B1Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compoundsAVENTIS PHARMA GMBH·Filed 1999·Granted Aug 28, 2001·44 cites·34 claims
- 1587US11053247B2Pyrimidinones as factor XIA inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jul 6, 2021·2 cites·9 claims
- 1687US7238671B2Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditionsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Jul 3, 2007·24 cites·19 claims
- 1787US6559313B2Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic propertiesAVENTIS PHARMA GMBH·Filed 2002·Granted May 6, 2003·21 cites·2 claims
- 1886US10336754B2Pyrimidinones as factor XIa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jul 2, 2019·2 cites·17 claims
- 1986US7632837B2Bicyclic heterocycles as cannabinoid-1 receptor modulatorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Dec 15, 2009·5 cites·15 claims
- 2086US7534763B2Sustained release GLP-1 receptor modulatorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted May 19, 2009·5 cites·25 claims
- 2184US7629342B2Azabicyclic heterocycles as cannabinoid receptor modulatorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Dec 8, 2009·7 cites·20 claims
- 2284US7378418B2Azabicyclic heterocycles as cannabinoid receptor modulatorsBRISTOL MYERS SQUIBB CO·Filed 2004·Granted May 27, 2008·24 cites·31 claims
- 2383US8143425B2Heterocyclic aromatic compounds useful as growth hormone secretagoguesEWING WILLIAM R·Filed 2005·Granted Mar 27, 2012·5 cites·11 claims
- 2482US8288404B2Pyrrolidine GPR40 modulatorsELLSWORTH BRUCE A·Filed 2010·Granted Oct 16, 2012·6 cites·18 claims
- 2582US6376472B1Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic propertiesAVENTIS PHARMA INC·Filed 1998·Granted Apr 23, 2002·24 cites·15 claims
- 2682US5441944ASubstituted cyclodextrin sulfates and their uses as growth modulating agentsUNIV PENNSYLVANIA·Filed 1992·Granted Aug 15, 1995·62 cites·18 claims
- 2782US5162336ATetrahydro-pyrido-indoles as cholecystokinin and gastrin antagonistsRHONE POULENC RORER PHARMA·Filed 1990·Granted Nov 10, 1992·27 cites·20 claims
- 2881US7166596B2Heterocyclic aromatic compounds useful as growth hormone secretagoguesBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Jan 23, 2007·9 cites·12 claims
- 2980US7910601B2Heterocyclic aromatic compounds useful as growth hormone secretagoguesBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Mar 22, 2011·2 cites·2 claims
- 3080US6034093ASubstituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compoundsRHONE POULENC RORER PHARMA·Filed 1998·Granted Mar 7, 2000·28 cites·30 claims
- 3179US10676477B2Factor XIa macrocycle inhibitors bearing a non-aromatic P2' groupBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 9, 2020·2 cites·12 claims
- 3279US7262195B2Compounds useful as motilin agonists and methodBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Aug 28, 2007·8 cites·7 claims
- 3378US11613554B2Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compoundsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 28, 2023·1 cites·17 claims
- 3478US9777001B2Macrocycles with aromatic P2′ groups as factor xia inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 3, 2017·3 cites·11 claims
- 3578US9133163B2Dihydropyrazole GPR40 modulatorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Sep 15, 2015·4 cites·15 claims
- 3678US7361766B2Bicyclic heterocycles as cannabinoid receptor modulatorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Apr 22, 2008·3 cites·6 claims
- 3778US7037910B2Azabicyclic heterocycles as cannabinoid receptor modulatorsBRISTOL MYERS SQUIBB·Filed 2004·Granted May 2, 2006·10 cites·17 claims
- 3877US12428421B2Pyrimidinones as factor XIA inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Sep 30, 2025·0 cites·31 claims
- 3977US7960349B2N-terminally modified GLP-1 receptor modulatorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Jun 14, 2011·2 cites·18 claims
- 4076US7314882B2Bicyclic heterocycles as cannabinoid receptor modulatorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Jan 1, 2008·2 cites·9 claims
- 4176US7220859B2Bicyclic heterocycles as cannabinoid receptor modulatorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted May 22, 2007·1 cites·8 claims
- 4276US7157461B2Substituted dihydropyrimidine inhibitors of calcium channel functionBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Jan 2, 2007·9 cites·8 claims
- 4375US8324241B2Triazolo compounds useful as DGAT1 inhibitorsHUANG YANTING·Filed 2009·Granted Dec 4, 2012·5 cites·8 claims
- 4475US7276608B2Tetrahydroquinoline derivatives as cannabinoid receptor modulatorsBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Oct 2, 2007·6 cites·4 claims
- 4574US12077558B2Phosphorus (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophosphorus (V) compoundsBRISTOL MYERS SQUIBB CO·Filed 2023·Granted Sep 3, 2024·0 cites·20 claims
- 4674US10336730B2Substituted glycine derived FXIA inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jul 2, 2019·1 cites·10 claims
- 4774US9714231B2Pyrrolidine GPR40 modulatorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jul 25, 2017·4 cites·15 claims
- 4874US9409908B2Dihydropyridone p1 as factor XIa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Aug 9, 2016·1 cites·14 claims
- 4974US5731315ASubstituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compoundsRHONE POULENC RORER PHARMA·Filed 1996·Granted Mar 24, 1998·20 cites·44 claims
- 5072US9604964B2Dihydropyrazole GPR40 modulatorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Mar 28, 2017·2 cites·12 claims
Showing the top 50 of 99 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when William R. Ewing files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →